GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

MK0557

Company
Merck Sharp & Dohme LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00092859

    A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

    Not yet reported Merck Sharp & Dohme LLC 1500 participants Est. completion 2005-06
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00092872

    A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

    Not yet reported Merck Sharp & Dohme LLC 359 participants Est. completion 2005-02
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00482430

    MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

    Not yet reported Merck Sharp & Dohme LLC 50 participants Est. completion 2008-10
    Other conditions: Paranoid Schizophrenia, Schizophrenia
    View official trial listing →
  • Completed NCT NCT00533481

    Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

    Not yet reported Merck Sharp & Dohme LLC 497 participants Est. completion 2004-12
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00533598

    A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

    Not yet reported Merck Sharp & Dohme LLC Est. completion 2003-06
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.